As direct-to-consumer (DTC) programs for prescribing GLP-1 weight-loss drugs gain traction, large retailers like Walmart, Costco, CVS, and Amazon are positioning themselves to capture a bigger slice of this growing market. With employers increasingly dropping insurance coverage for GLP-1 medications such as Wegovy and Zepbound, more patients are turning to these retail chains to access affordable prescriptions. For these retailers, GLP-1 drugs are more than a single product sale—they serve as a gateway to build long-term customer relationships that extend beyond medication to include other retail items.

These programs often offer introductory prices as low as $25 per month, with incentives for timely refills, effectively creating a loyalty system that keeps consumers returning. Walmart, for example, expanded its Better Care Services platform to bundle GLP-1 prescriptions with weight management support, while Amazon launched a GLP-1 program through Amazon One Medical and Amazon Pharmacy, leveraging same-day delivery in thousands of cities. This strategy aims not only to gain prescription customers but also to increase foot traffic that could boost overall retail sales, a critical factor in an industry where customer retention is key.

Despite the potential growth, major retail pharmacy chains have struggled with profitability in healthcare, as seen with Walmart’s recent closure of health clinics and Amazon’s shutdown of several healthcare initiatives. Additionally, the shift toward DTC GLP-1 prescriptions creates challenges for independent pharmacies, which lose volume to larger chains offering lower prices and extensive support programs. These independents worry about patient safety since they are often excluded from DTC programs and may lack visibility into a patient’s full medication profile, increasing the risk of drug interactions.

Experts caution that while GLP-1 drugs are effective tools, they don’t function optimally without expert clinical care. The rush to offer the lowest prices risks fragmenting care and overlooking broader health needs. Still, the move toward DTC prescribing reflects a broader trend of retailers vying to become the primary “front door” for obesity treatment amidst shifting employer benefits. For now, the major retail players appear to be capitalizing on this transition, betting that the long-term customer relationships forged through GLP-1 prescriptions will generate substantial future revenue.